M. La-posologie and I. , 76 2.3.3. La durée minimale de traitement, p.78

.. Après-la-prescription-surveillance-du-traitement, 82 3.4.1. L'arrêt du traitement en cas de cible, p.82

. Le-choix-du-thème and . Du-champ, le choix des critères 3. le choix de la méthode de mesure 4. le recueil des données 5. l'analyse des résultats : mise en évidence de points forts et points faibles 6. les plans d'actions d'amélioration et la réévaluation -« l'observation médicale

L. Oui, Non ou NA (non approprié)) pour chaque critère sont reportées dans un tableur EXCEL (Microsoft®)

. Références-bibliographiques-1, H. Wirth, R. Hürlimann, and T. Flückiger, Les AINS et les inhibiteurs de la cox-2: principaux effets indésirables, Forum Med Suisse, issue.6, pp.284-90, 2006.

M. Wolfe, D. Lichtenstein, and G. Singh, Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs, New England Journal of Medicine, vol.340, issue.24, pp.1888-99, 1999.
DOI : 10.1056/NEJM199906173402407

H. Vonkeman, R. Klok, and M. Postma, Direct Medical Costs of Serious Gastrointestinal Ulcers among Users of NSAIDs, Drugs & Aging, vol.333, issue.6, pp.681-90, 2007.
DOI : 10.2165/00002512-200724080-00005

R. Johnson, M. Hornbrook, and R. Hooker, Analysis of the Costs of NSAID-Associated Gastropathy, PharmacoEconomics, vol.12, issue.1, pp.76-88, 1997.
DOI : 10.2165/00019053-199712010-00008

. Thalès, Profil des patients traités par AINS en Etude commandée par la HAS, 2007.

R. Schoen and R. Vender, Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage, The American Journal of Medicine, vol.86, issue.4, pp.449-58, 1989.
DOI : 10.1016/0002-9343(89)90344-6

M. Wolfe and A. Soll, The physiology of gastric acid secretion, N Engl J Med, vol.319, pp.1707-1722, 1988.

G. Singh, D. Ramey, and D. Morfeld, Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A propective observational cohort study, Arch Intern Med, issue.156, pp.1530-1566, 1996.

G. Singh, Recent considerations in nonsteroidal anti-inflammatory drug gastropathy, The American Journal of Medicine, vol.105, issue.1, pp.31-38, 1998.
DOI : 10.1016/S0002-9343(98)00072-2

A. Lanas, M. Perez-aisa, and F. Feu, A Nationwide Study of Mortality Associated with Hospital Admission Due to Severe Gastrointestinal Events and Those Associated with Nonsteroidal Antiinflammatory Drug Use, The American Journal of Gastroenterology, vol.114, issue.3, pp.100-1685, 2005.
DOI : 10.1111/j.1572-0241.2003.07517.x

D. Popsai, I. Sobhani, and M. Migon, Maladie ulcéreuse duodénale et gastrique non compliquée, Paris: Flammarion, pp.329-375, 2005.

M. Feldman, Can Gastroduodenal Ulcers in NSAID Users Be Prevented?, Annals of Internal Medicine, vol.119, issue.4, pp.337-346, 1993.
DOI : 10.7326/0003-4819-119-4-199308150-00015

P. Pouyanne, F. Haramburu, and J. Imbs, Admissions to hospital caused by adverse drug reactions: cross sectional incidence study, BMJ, vol.320, issue.7241, p.1036, 2000.
DOI : 10.1136/bmj.320.7241.1036

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC27343

L. Coles, J. Fries, and R. Kraines, From experiment to experience: Side effects of nonsteroidal anti-inflammatory drugs, The American Journal of Medicine, vol.74, issue.5, pp.820-828, 1983.
DOI : 10.1016/0002-9343(83)91073-2

C. Bombardier, L. Laine, and A. Reicin, Comparaison of upper gastrointestinal toxicity of rofecoxib and naproxene in patients with rheumatoid arthritis. VIGOR Study Group, N Engl J Med, issue.21, pp.343-1520, 2000.

E. Rahme, M. Bardou, and K. Dasgupta, Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study, Rheumatology, vol.46, issue.2, pp.265-72, 2007.
DOI : 10.1093/rheumatology/kel223

M. Udd, P. Miettinen, and A. Palmu, Analysis of the risk factors and their combinations in acute gastroduodenal ulcer bleeding: A case-control study, Scandinavian Journal of Gastroenterology, vol.23, issue.12, pp.1395-403, 2007.
DOI : 10.1046/j.1365-2036.1999.00488.x

C. Hawkey, L. Laine, and T. Simon, Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatism, vol.43, issue.2, pp.370-377, 2000.
DOI : 10.1002/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D

L. Laine, Non steroidal anti-inflammatory drug gastropathy, Gastrointest Endosc Clin North Am, issue.6, pp.489-504, 1996.

D. Henry, A. Dobson, and C. Turner, Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs, Gastroenterology, vol.105, issue.4, pp.1078-88, 1993.
DOI : 10.1016/0016-5085(93)90952-9

S. Gabriel, L. Jaakimainen, and C. Bombardier, Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs, Annals of Internal Medicine, vol.115, issue.10, pp.787-96, 1991.
DOI : 10.7326/0003-4819-115-10-787

P. Malfertheiner, F. Megraud, O. Morain, and C. , Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report, Gut, vol.56, issue.6, pp.772-81, 2007.
DOI : 10.1136/gut.2006.101634

G. Papatheodoridis, S. Sougioultzis, and A. Archimandritis, Effects of Helicobacter pylori and Nonsteroidal Anti-Inflammatory Drugs on Peptic Ulcer Disease: A Systematic Review, Clinical Gastroenterology and Hepatology, vol.4, issue.2, pp.130-172, 2006.
DOI : 10.1016/j.cgh.2005.10.006

D. Kaufman, J. Kelly, and B. Wilhom, The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption, The American Journal of Gastroenterology, vol.131, issue.11, pp.3189-96, 1999.
DOI : 10.1111/j.1572-0241.1999.01517.x

A. Lanas, E. Bajador, and P. Serrano, Nitrovasodilators, Low-Dose Aspirin, Other Nonsteroidal Antiinflammatory Drugs, and the Risk of Upper Gastrointestinal Bleeding, New England Journal of Medicine, vol.343, issue.12, pp.834-843, 2000.
DOI : 10.1056/NEJM200009213431202

A. Lanas, G. Rodriguez, L. Arroyo, and M. , Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations, Gut, vol.55, issue.12, pp.1731-1739, 2006.
DOI : 10.1136/gut.2005.080754

K. Thomopoulos, K. Mimidis, and G. Theocharis, Acute upper gastrointestinal bleeding inpatients on long-term oral anticoagulation therapy: endoscopic findings, clinical management and outcome, World J Gastroenterol, issue.11, pp.1365-1373, 2005.
DOI : 10.3748/wjg.v11.i9.1365

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4250686

M. Farkouh, H. Kirshner, and R. Harrington, Comparaison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event trial (TARGET), Lancet, vol.354, pp.675-84, 2004.

S. Gutthann, G. Rodriguez, L. Raiford, and D. , Nonsteroidal Anti-inflammatory Drugs and the Risk of Hospitalization for Acute Renal Failure, Archives of Internal Medicine, vol.156, issue.21, pp.2433-2442, 1996.
DOI : 10.1001/archinte.1996.00440200041005

D. Henry, J. Page, and I. Whyte, Consumption of nonsteroidal antiinflammatory drugs and the development of functional renal impairement in elderly subjects. Results of a case control study, Br J Clin Pharmacol, issue.44, pp.85-90, 1997.

M. Stillman and P. Schlesinger, Nonsteroidal anti-inflammatory drug nephrotoxicity. Should we be concerned ? Arch Intern Med, p.268, 1990.
DOI : 10.1001/archinte.1990.00390140024006

C. Brater, C. Harris, and J. Redfern, Renal Effects of COX-2-Selective Inhibitors, American Journal of Nephrology, vol.21, issue.1, pp.1-15, 2001.
DOI : 10.1159/000046212

J. Schwartz, M. Malice, and K. Lasseter, Effect of rofecoxib, celecoxib, and naproxene on blood pressure and urinary sodium excretion in elderly volunteers, European congress of Rheumatology, 2001.

J. Roujeau, J. Kelly, and B. Rzany, Medication use and the risk of Stevens-Johnson syndrome or toxidermal necrolysis, N Engl J Med, vol.60, pp.1600-1607, 1995.

K. Skeith, M. Wright, and P. Davis, Differencies in NSAID tolerability profile. Fact or fiction? Drug Saf, pp.183-95, 1994.
DOI : 10.2165/00002018-199410030-00001

D. Kaufman, J. Keely, and J. Jurgelon, Drugs in the etiology of agranulocytosis and aplastic anemia, Eur J Hematol, vol.60, pp.23-30, 1996.

H. Autorité and D. Santé, HAS) Guide méthodologique: Elaboration de critères de qualité pour l'évaluation et l'amélioration des pratiques professionnelles, 2007.

H. Autorité and D. Santé, HAS) Audit clinique ciblé appliqué à la "Prise en charge du patient sous AVK, 2006.

H. Autorité and D. Santé, HAS) Prescription médicamenteuse chez le sujet âgé (3) -Lors d'une hospitalisation -évaluation du dossier, 2006.

A. Spehner and M. Welsch, Evaluation des pratiques professionnelles : un audit clinique sur la prescription et la surveillance des traitements par anti-inflammatoires non stéroïdiens en médecine générale, Thèse Méd Gén, pp.1-112, 2010.

A. European-medecines, Key elements for the summaries of product characteristics of the non-selective NSAIDs piroxicam, ketoprofen and ketorolac adopted by the CHMP, 2006.

V. Dictionnaire, Résumé des caractéristiques du produit (RCP): kétoprofène, 2009.

H. Autorité and D. Santé, HAS) Bon usage du médicament: les inhibiteurs de la pompe à proton chez l'adulte, 2009.

A. Price-forbes, R. Callaghan, and M. Allen, A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines, Rheumatology, vol.44, issue.7, pp.44-921, 2005.
DOI : 10.1093/rheumatology/keh642

J. Kitchen and D. Kane, Non-steroidal anti-inflammatory drug prescriptions in hospital inpatients: are we assessing the risks?, Irish Journal of Medical Science, vol.26, issue.2, pp.357-60, 2010.
DOI : 10.1007/s11845-010-0496-0

T. Schaeverbeke, E. Vicaut, and A. Cohen, Comment ??valuer le risque cardiovasculaire et r??nal ?? l?????chelon individuel?, La Presse M??dicale, vol.35, pp.35-40, 2006.
DOI : 10.1016/S0755-4982(06)74938-7

W. Kannel, T. Dawber, and A. Kagan, Risk Factors in the Development of Coronary Heart Disease. Six Year Follow-up Experience???The Framingham Study., Annals of Internal Medicine, vol.54, issue.5, pp.33-50, 1961.
DOI : 10.7326/0003-4819-54-5-1035_1

S. Chaussade, B. Avouac, and E. Vicaut, What is the impact of cardiovascular and renal complications on the benefit/risk ratio of the NSAIDs, Presse Med, pp.35-61, 2006.

R. Conroy, K. Pyorala, and A. Fitzgerald, Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project, European Heart Journal, vol.24, issue.11, pp.987-1003, 2003.
DOI : 10.1016/S0195-668X(03)00114-3

C. Huerta, J. Castellsague, and C. Varas-lorenzo, Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population, American Journal of Kidney Diseases, vol.45, issue.3, pp.531-540, 2005.
DOI : 10.1053/j.ajkd.2004.12.005

T. Schaeverbeke, F. Heloire, and G. Deray, How to watch over a patient treated with NSAID in relation to the cardiovascular and renal risk

C. Bou, Prescription des AINS chez les plus de 70 ans: évaluation de la pratique sur un échantillon de population de trois cabinets de médecine générale, Mémoire DES Méd Gén, pp.1-31, 2007.

G. Rodriguez, L. , B. Tolosa, and L. , Risk of Upper Gastrointestinal Complications Among Users of Traditional NSAIDs and COXIBs in the General Population, Gastroenterology, vol.132, issue.2, pp.498-506, 2007.
DOI : 10.1053/j.gastro.2006.12.007

D. Menu, P. Brun, and P. Desmidt, Prescription des AINS en Bourgogne chez la personne âgée de plus de 70 ans, Rev Prat, vol.642, pp.248-52, 2004.

L. Parc, J. Jeandel, C. Hillon, and P. , Enqu??te image: une ??tude observationnelle sur les prescriptionsd'anti-inflammatoires non st??ro??diens et de gastroprotecteurs. ??valuation des modes de prescription selon le profil des patients, Revue du Rhumatisme, vol.71, issue.71, pp.157-160, 2004.
DOI : 10.1016/S1169-8330(04)80020-6

P. Lévy, S. Fanello, and J. Pivette, Anti-inflammatoires non stéroïdiens et risques iatrogènes potentiels : analyse des données de l'assurance maladie, Rev Med Ass Maladie, vol.36, issue.2, pp.153-61, 2005.

P. Goupille, I. Logeart, and B. Combe, Naturalistic survey on nonsteroidal antiinflammatory treatment in patients with musculoskeletal pain, Joint Bone Spine, vol.70, issue.3, pp.219-244, 2003.
DOI : 10.1016/S1297-319X(03)00047-2

P. Ekstrom, L. Carling, and S. Wetterhus, Prevention of peptic ulcer and dyspeptic syndrome with omeprazol in patients receiving continuous nonsteroidal anti-inflammatory drug therapy. A nordic multicenre study

D. Benhamou, H. Bouaziz, and N. Zerrouk, Audit of ketoprofen prescribing after orthopedic and general surgery, Canadian Journal of Anesthesia/Journal canadien d'anesth??sie, vol.275, issue.2, pp.109-122, 1999.
DOI : 10.1007/BF03012543

K. Johnell and J. Fastbom, Concomitant Use of Gastroprotective Drugs among Elderly NSAID/COX-2 Selective Inhibitor Users, Clinical Drug Investigation, vol.17, issue.5, pp.687-95, 2008.
DOI : 10.2165/00044011-200828110-00002

Y. Loke, A. Trivedi, and S. Singh, Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs, Alimentary Pharmacology & Therapeutics, vol.22, issue.1, pp.31-40, 2007.
DOI : 10.1111/j.1365-2036.2007.03541.x

R. Fara, M. Rasoloherimampiononiaina, and T. Rajaonarivony, Connaissance de la pharmacologie des anti-inflammatoires non stéroïdiens par les médecins de la capitale d'Antananarivo, pp.100-102, 2008.
DOI : 10.1016/j.annfar.2007.10.039

W. Ray, C. Stein, and V. Byrd, Educational Program for Physicians to Reduce Use of Non-Steroidal Anti-Inflammatory Drugs Among Community-Dwelling Elderly Persons, Medical Care, vol.39, issue.5, pp.425-460, 2001.
DOI : 10.1097/00005650-200105000-00003

J. Curtis, J. Olivieri, and J. Allison, A group randomized trial to improve safe use of nonsteroidal anti-inflammatory drugs, Am J Manag Care, vol.11, issue.9, pp.537-580, 2005.

F. Lanza, F. Chan, and E. Quigley, Guidelines for Prevention of NSAID-Related Ulcer Complications, The American Journal of Gastroenterology, vol.328, issue.3, pp.728-766, 2009.
DOI : 10.1038/ajg.2009.115

R. Flipo and P. Bertin, Connaissance par les médecins et les patients du risque de complications digestives des AINS, Presse Med, vol.32, issue.37, pp.4-48, 2003.

. Réunion-pluridisciplinaire-médicale-et-paramédicale-d, étage hebdomadaire -Orientation du patient : Discussion au colloque Médico-Chirurgical hebdomadaire Sortie Soins de suite à l'HRU SORTIE DU PATIENT : Examen clinique médical Evaluation quantitative de la douleur : EVA lombaire et radiculaire Prise de RDV de CS : Médecin Généraliste

. La-réponse-est-oui-si, en cas de prescription concomitante d'AINS et de traitement à risque, toutes les mesures de surveillance clinique et biologique sont appliquées

S. Au-moins-un-facteur-de-risque-digestif, parmi âge >65 ans, AAP, AVK, antécédent d'ulcère ou hémorragie digestive) : AINS défini comme contre-indiqué